How modest fructose intake harms body fat and whether blocking the fructose enzyme helps
Official title: Exploring the mechanisms by which dietary fructose primarily impairs white adipose, not hepatic, function: insights from a novel ketohexokinase antisense oligonucleotide
Funded at VA Connecticut Healthcare System · NIH-11213921 · Data updated 2026-11-12
Looking at whether blocking the enzyme that processes fructose can protect fat tissue and blood sugar control in people at risk for type 2 diabetes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Connecticut Healthcare System NIH-funded |
| Lab location | 1 site (West Haven, United States) |
| Project start | October 1, 2023 |
| Project end | September 30, 2027 |
| Funding year | 2026 |
| NIH project number | 5I01BX005790-03 |
| Project ID | NIH-11213921 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with or at high risk for type 2 diabetes, especially those who consume sugary or fructose-containing foods and beverages, would be the intended beneficiaries of this line of research.
✕Less likely to help
People without metabolic risk from fructose intake or whose conditions are unrelated to adipose insulin resistance are unlikely to benefit directly from this specific research.
What this research studies
This research uses laboratory models to mimic modest, human-like fructose intake and tests a molecule that blocks ketohexokinase (the main fructose-processing enzyme). The team found early evidence in animals that blocking this enzyme improved how fat tissue responds to insulin. They are probing the chain of events linking fructose to changes in blood fats and fat-cell insulin signaling to understand why fat tissue — not the liver — seems most affected. The goal is to learn whether targeting this enzyme could prevent fat dysfunction that later worsens blood sugar and lipid control.
Why it matters
Potential benefit: If successful, this work could point to new treatments that protect fat tissue, improve insulin sensitivity, and help prevent or treat type 2 diabetes and related metabolic problems.
How similar studies have gone: Preclinical work in animals, including the project's own rat experiments, has shown that blocking ketohexokinase can improve adipose insulin action, but human clinical data are limited.
Where this research is happening
-
VA Connecticut Healthcare System
West Haven, United States Active
Researchers
- Principal investigator: Samuel, Varman T — VA Connecticut Healthcare System
- Study coordinator: Samuel, Varman T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.